Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Aphria Inc. APHA

Healthcare Drug Manufacturers - Major Cannabis
Aphria, which is headquartered in Ontario, produces and sells medicinal and recreational cannabis. The company operates through retail and wholesale channels in Canada and internationally. Aphria is a main distributor of medical cannabis to Germany and has operations in over 10 countries outside of Canada. However, it does not have exposure to the U.S. CBD or THC markets due to the constraints of federal prohibition. It has some U.S. exposure through the acquisition of SweetWater, a craft brewer


NDAQ:APHA - Post by User

Aphria Inc. > Aphria Rating change Apr 4 - Apr 10, 2021
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(1830)
•••
Comment by DaveInCalgaryon Apr 08, 2021 3:29pm
191 Views
Post# 32958279

RE:Aphria Rating change Apr 4 - Apr 10, 2021

RE:Aphria Rating change Apr 4 - Apr 10, 2021Aaron Grey Ranked 370 out of 7,432 analysts, with a BUY rating and Target Price of $32.82 has been accurate often.

From Aphria's current price at $20.44 we stand to GAIN $12.38 = 60.6% (likely by mid July)
<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities